Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.15M | 789.00K | 351.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.15M | 789.00K | 351.00K | -- | -- |
| Cost of Revenue | 53.45M | 55.60M | 59.70M | 62.81M | 63.99M |
| Gross Profit | -52.30M | -54.82M | -59.35M | -62.81M | -63.99M |
| SG&A Expenses | 35.34M | 39.16M | 44.08M | 47.31M | 50.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.79M | 94.76M | 103.78M | 110.12M | 114.11M |
| Operating Income | -87.64M | -93.97M | -103.43M | -110.12M | -114.11M |
| Income Before Tax | -46.90M | 5.70M | 5.39M | -53.85M | -60.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.90 | 5.70 | 5.39 | -53.85 | -60.19 |
| Earnings from Discontinued Operations | -- | -- | 0.00 | 139.81M | 133.14M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.90M | 5.70M | 5.39M | 85.97M | 72.95M |
| EBIT | -87.64M | -93.97M | -103.43M | -110.12M | -114.11M |
| EBITDA | -83.80M | -89.84M | -99.17M | -105.50M | -109.13M |
| EPS Basic | -5.07 | 0.76 | 0.60 | 11.29 | 9.22 |
| Normalized Basic EPS | -5.21 | -5.31 | -4.04 | -6.86 | -7.59 |
| EPS Diluted | -5.08 | 0.75 | 0.58 | 11.27 | 9.20 |
| Normalized Diluted EPS | -5.21 | -5.31 | -4.03 | -6.86 | -7.59 |
| Average Basic Shares Outstanding | 36.31M | 35.44M | 34.77M | 33.64M | 32.48M |
| Average Diluted Shares Outstanding | 36.33M | 35.46M | 34.80M | 33.66M | 32.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |